Low-Intensity Focused Ultrasound for Cocaine Use Disorder

Sponsor
University of Virginia (Other)
Overall Status
Recruiting
CT.gov ID
NCT05857852
Collaborator
(none)
30
1
2
24
1.2

Study Details

Study Description

Brief Summary

This study aims to understand the role of Low-Intensity Focused Ultrasound on craving levels for cocaine as evidenced by diagnostic imaging of the dorsal anterior insula (dAI) and subjective ratings. Data analysis will serve to show if 1) LIFU is safe and effective and to 2) examine the effects of LIFU on dAI BOLD activity and craving in response to cocaine cue-exposure. The study will screen 60 individuals with Cocaine Use Disorder (CUD) to arrive at 30 enrolled subjects, based on a 2:1 screen/randomization ratio.

Condition or Disease Intervention/Treatment Phase
  • Device: Low-Intensity Focused Ultrasound
  • Device: Sham LIFU device
N/A

Detailed Description

This is a randomized single-blind, active, sham-controlled study.

This study will enroll thirty (30) individuals, aged 18 years and older, that meet the criteria for CUD. Participants will be recruited from the general population and will be asked to complete cognitive testing and measures, self-reported craving measures, and diagnostic exams including magnetic resonance imaging (MRI) and Computed Tomography (CT). Participants will also undergo functional MRI which entails being shown cocaine-related photos at regular intervals.

All participants will receive LIFU and sham interventions, but will be randomized to one of two sessions, and will return one month after the second session for an in-person follow-up. In total, there are five (5) in-person visits and two (2) phone calls to assess for adverse events, conducted over eight (8) weeks.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Intervention Model Description:
At each of two intervention visits, participants will receive either LIFU or sham. At the completion of both visits, all participants will have received both, LIFU and sham.At each of two intervention visits, participants will receive either LIFU or sham. At the completion of both visits, all participants will have received both, LIFU and sham.
Masking:
Triple (Participant, Care Provider, Outcomes Assessor)
Masking Description:
Single-blind study
Primary Purpose:
Health Services Research
Official Title:
Low-Intensity Focused Ultrasound for Cocaine Use Disorder
Actual Study Start Date :
Mar 1, 2023
Anticipated Primary Completion Date :
Mar 1, 2025
Anticipated Study Completion Date :
Mar 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: Low-Intensity Focused Ultrasound (LIFU)

All subjects to receive LIFU and Sham in a randomized order.

Device: Low-Intensity Focused Ultrasound
Low-Intensity Focused Ultrasound administration to right dorsal anterior insula, in one of two sessions

Sham Comparator: Sham LIFU

All subjects to receive LIFU and Sham in a randomized order.

Device: Sham LIFU device
Sham LIFU device administered in one of two sessions

Outcome Measures

Primary Outcome Measures

  1. Percent reduction in Bold Oxygen Level Dependent (BOLD)% signal change in response to cocaine cue exposure [8 weeks]

    Evidence on MRI of BOLD activity in the dAI region

  2. Decrease in average craving score by 25% for LIFU compared to sham [8 weeks]

    Participant, subjective rating of cocaine-related craving

  3. No evidence of neurological or other adverse events related to LIFU [8 weeks]

    MRI images will show congruity of brain data over course of study

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Ages 18 years and older with a history of cocaine use disorder

  • Have a current (past 6 months) DSM-5 diagnosis of cocaine use disorder (4 or more symptoms) assessed using the MINI neuropsychiatric interview

  • Have a blood alcohol content by breathalyzer, equal to 0.000 when informed consent document is signed

  • Ability to abstain from cocaine use at key points during study

  • Willingness and ability to comply with scheduled visits and study procedures

  • Ability to lie down for extended periods of time for imaging tests

  • Will have reliable transportation throughout study

  • Will have a stable residence during the 2 weeks prior to randomization and not be at risk of losing housing in next 2 months

  • Must meet criteria to have magnetic resonance imaging (MRI)

Exclusion Criteria:

• Please contact PI or Study Coordinator for more details.

Contacts and Locations

Locations

Site City State Country Postal Code
1 UVA Center for Leading Edge Addiction Research Charlottesville Virginia United States 22903

Sponsors and Collaborators

  • University of Virginia

Investigators

  • Principal Investigator: Nassima Ait-Daoud Tiouririne, MD, University of Virginia, Center for Leading Edge Addiction Research

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Nassima Ait-Daoud Tiouririne, Professor of Psychiatry and NB Sciences, University of Virginia
ClinicalTrials.gov Identifier:
NCT05857852
Other Study ID Numbers:
  • HSR220247
First Posted:
May 15, 2023
Last Update Posted:
May 15, 2023
Last Verified:
May 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Keywords provided by Nassima Ait-Daoud Tiouririne, Professor of Psychiatry and NB Sciences, University of Virginia
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 15, 2023